Rebecca Tollervey - July 16, 2024 EPO case law for antibodies – 2024 update In 2023 we published a pair of articles reviewing EPO case law in the field of antibodies, ...
Edward Couchman - March 25, 2024 Cancer-killing bacteria: past, present and future While bacteria have frequently made the medical news in recent years due to the urgent problem of ...
Edward Couchman - February 7, 2024 Genes as Medicines: Treating the Untreatable In 2023, gene therapy hit the headlines in the UK, when the BBC reported the cure of a toddler with ...
Edward Couchman - August 7, 2023 Cells as medicines: the promise of cell therapy Cell therapy is one of the most exciting areas of medical science, with recent years having seen ...
Rebecca Tollervey - May 9, 2023 Patenting antibodies – the latest developments from the EPO Boards of Appeal: Part 2 – inventive step We have conducted a review of Board of Appeal decisions relating to antibody patents published ...
Eliot Ward - May 4, 2023 The ball is rolling at the FDA for microbiome therapies The FDA was busy last week! Off the back of the first approval for faecal microbiota transplant ...
Natalie Vaughan - February 23, 2023 Microbiome claims around the world: how to define your microbe? A booming commercial interest in harnessing the human microbiome for therapeutic uses has led to a ...
Rebecca Tollervey - February 1, 2023 Patenting antibodies – the latest developments from the EPO Boards of Appeal The prosecution of patent applications relating to antibodies involves particular considerations. ...
Edward Couchman - November 11, 2022 Enablement Requirements for Antibody Claims to be Reviewed by US Supreme Court In a development which will be of interest to biotech companies, particularly those working in the ...
Edward Couchman - June 15, 2021 Cell therapy: repairing and rebuilding the body Recent advances in medicine have, for the first time, allowed physicians to directly intervene in ...